Developer docs
API playgroundTry for free, no card

Search company profiles

Charlesson

Full company profile

uuid002isf4

Namestring
Charlesson
Legal namestring
EyeCRO
Company typeenum
Private
Founded yearint
2004
Descriptiontext

EyeCRO is a preclinical contract research organization (CRO) specializing in ophthalmic drug development for pharmaceutical and biotech sponsors. The company provides a fully integrated platform covering in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, dosing and drug delivery, histology and pathology, and ophthalmic imaging and physiology across mouse, rat, and rabbit models. Its two AAALAC International-accredited facilities—headquartered in Oklahoma City, OK with a secondary site in Ann Arbor, MI—house both the vivarium and the bioanalytical laboratory, enabling sponsors to move from dosing to quantification under a single study plan with one point of contact.

EyeCRO's core technology platform is built on two pillars: an integrated CRO workflow that eliminates cross-vendor sample handoffs, and the proprietary MiDROPS® microemulsion drug ocular penetration system. MiDROPS® uses thermodynamically stable, self-assembling microemulsions to formulate high concentrations of lipophilic small molecules for anterior and posterior segment delivery via eyedrops, and is protected by broad US and international patents covering millions of formulations. The company maintains over 20 validated preclinical disease models spanning anterior segment, inflammation/autoimmune, outer retinal degeneration, inner retinal degeneration, and retinal vascular indications.

The business model is fee-for-service professional services (project-based preclinical research contracts) supplemented by MiDROPS® licensing/royalty revenue. Go-to-market is enterprise B2B, executed through direct outreach, ARVO conference presence, and scientific publication visibility. Pricing is not publicly disclosed and is structured as project-specific quotes. The company is privately held with no disclosed ownership, funding, or revenue figures, and is currently operating with active news publishing and conference participation through May 2026.

Short descriptiontext

EyeCRO is a preclinical contract research organization providing integrated ophthalmic drug development services—including in-life efficacy studies, bioanalytical analysis, and the proprietary MiDROPS® eyedrop formulation technology—to pharmaceutical and biotech sponsors developing eye disease therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical ophthalmic research, contract research services, ophthalmic drug development, bioanalytical laboratory services, preclinical disease models
Industry2 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

EyeCRO provides fee-for-service preclinical ophthalmic research contracts, including in-life efficacy studies, bioanalytical services, toxicology/PK studies, and formulation development. Revenue is generated through project-based contracts with pharmaceutical and biotech sponsors.

eyecro.com
2MiDROPS® Licensing
TypeLicensing Royalties
Description

The company offers its MiDROPS® microemulsion technology for eyedrop formulations, protected by broad patents issued in the US and worldwide. Licensing revenue from the formulation library.

eyecro.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MiDROPS®
Description

Microemulsion Drug Ocular Penetration System - a proprietary microemulsion technology for ophthalmic drug delivery using thermodynamically stable, self-assembling vehicles that can formulate high concentrations of drugs for anterior and posterior segment delivery. The technology is protected by broad patents issued in the US and worldwide.

eyecro.com
Core offering1 text field

EyeCRO provides a fully integrated platform for preclinical ophthalmic drug development, delivering in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, and eyedrop formulations under one roof. The company supports pharmaceutical and biotech sponsors with multi-route drug administration, ophthalmic imaging, histology, and 22 validated preclinical disease models, complemented by its proprietary MiDROPS® microemulsion formulation technology for ocular drug delivery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Studies move from dosing to quantification without delays, sample degradation risks, or coordination across vendors
Product overview1 text field

EyeCRO operates as a fully integrated preclinical ophthalmic research platform offering comprehensive drug development services from in-life efficacy studies through bioanalytical quantitation. The core offering combines EyeCRO's research services with MiDROPS®, a proprietary microemulsion drug delivery technology for ophthalmic formulations. Supporting service modules include bioanalytical services (LC-MS/MS, HPLC, ELISA), dosing and drug delivery, histology and pathology, ophthalmic imaging and physiology, and proprietary software and analysis. The company maintains 22 validated preclinical disease models spanning anterior segment, inflammation/autoimmune, outer retinal degeneration, inner retinal degeneration, and retinal vascular conditions.

Product and service7 records
1EyeCRO Preclinical Research Services
CategoryContract Research Services
Description

Fully integrated preclinical ophthalmic drug development platform providing in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, and eyedrop formulations under one roof for pharmaceutical and biotech sponsors.

2MiDROPS® Microemulsion Drug Ocular Penetration System
CategoryDrug Delivery Technology / Formulation
Description

Proprietary microemulsion technology for eyedrop formulations of lipophilic small molecules, enabling delivery of high drug concentrations to both anterior and posterior eye segments; protected by broad patents issued in the US and worldwide.

3Bioanalytical Services
CategoryContract Research Services
Description

Laboratory services including LC-MS/MS, HPLC, ELISA, and multiplex immunoassay with optimized ocular tissue extraction protocols for mouse, rat, and rabbit specimens.

4Dosing & Drug Delivery Services
CategoryContract Research Services
Description

Drug administration services via intravitreal, subretinal, subconjunctival, topical, and systemic routes across mouse, rat, and rabbit species.

5Histology & Pathology Services
CategoryContract Research Services
Description

Full histological processing, H&E staining, IHC, and digital image quantification for ocular tissue analysis.

6Ophthalmic Imaging & Physiology Services
CategoryContract Research Services
Description

In vivo retinal imaging services including ERG, OCT, fundus photography, and slit-lamp biomicroscopy across multiple species.

7Preclinical Disease Models
CategoryContract Research Services
Description

22 validated preclinical disease models across retinal, corneal, inflammatory, and optic nerve disease areas including Dry Eye Disease, Geographic Atrophy, Diabetic Retinopathy, Retinal Vein Occlusion, and others.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Marseille Declaration
Strategic tierMinorTypeOthers
Description

EyeCRO is a signatory to the Marseille Declaration, a commitment to ethical business practices and transparency in preclinical research operations.

eyecro.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sinclair Research is a preclinical CRO with ophthalmic capabilities, AAALAC-accredited facilities, and species expertise (mouse, rat, rabbit, dog, non-human primate). Directly comparable to EyeCRO for in-life preclinical ophthalmic efficacy studies.

TypeBroad incumbent
Description

Labcorp Drug Development is a top global CRO offering preclinical and clinical services with ophthalmic drug development capabilities. A broad incumbent that competes with EyeCRO at the high end of ophthalmic sponsor engagements.

3Absorption Systems
TypeDirect peer
Description

Absorption Systems is a preclinical CRO offering bioanalytical, ADME, and drug delivery services with ophthalmic capabilities. Comparable to EyeCRO for bioanalytical and ocular drug delivery work, with a broader overall ADME portfolio.

TypeDirect peer
Description

IONTOX specializes in ocular toxicology, in vitro and ex vivo ocular assays, and preclinical ophthalmic safety assessment. Comparable to EyeCRO's preclinical ocular toxicology/PK service modules, though focused more narrowly on safety.

TypeDirect peer
Description

Ora is a leading ophthalmic-specialty CRO offering preclinical and clinical research services. It is the closest direct peer to EyeCRO — both target ophthalmic drug development sponsors and compete for similar preclinical ophthalmic contracts, though Ora has a much larger clinical-stage footprint.

TypeRegional player
Description

Bioneeds is a preclinical CRO based in India offering ophthalmic efficacy/toxicology services at cost-advantaged pricing. A regional competitor that pressures US-based preclinical CRO economics, particularly for cost-sensitive biotech sponsors.

TypeBroad incumbent
Description

WuXi AppTec offers preclinical CRO services with ophthalmic capabilities and is one of the largest preclinical research platforms globally. Competes for ophthalmic preclinical contracts from sponsors seeking scale, geographic reach, and integrated chemistry-biology capabilities.

TypeBroad incumbent
Description

Pharmaron is a global CRO/CDMO with preclinical research capabilities across multiple therapeutic areas including ophthalmology. Provides scale, geographic reach, and integrated chemistry/manufacturing capabilities that small specialist CROs cannot match.

TypeBroad incumbent
Description

Charles River is one of the largest global preclinical CROs with broad ophthalmic research capabilities across multiple species and indications. Competes with EyeCRO for larger sponsor preclinical ophthalmic contracts but offers many additional therapeutic-area capabilities.

TypeBroad incumbent
Description

Frontage Laboratories is a CRO providing preclinical and bioanalytical services across multiple therapeutic areas, including ophthalmology following its Absorption Systems acquisition. Competes with EyeCRO for integrated preclinical ophthalmic contracts.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Charlesson

Preclinical Contract Research Servicescharlessonllc.com

EyeCRO is a preclinical contract research organization providing integrated ophthalmic drug development services—including in-life efficacy studies, bioanalytical analysis, and the proprietary MiDROPS® eyedrop formulation technology—to pharmaceutical and biotech sponsors developing eye disease therapeutics.

What Charlesson does

EyeCRO is a preclinical contract research organization (CRO) specializing in ophthalmic drug development for pharmaceutical and biotech sponsors. The company provides a fully integrated platform covering in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, dosing and drug delivery, histology and pathology, and ophthalmic imaging and physiology across mouse, rat, and rabbit models. Its two AAALAC International-accredited facilities—headquartered in Oklahoma City, OK with a secondary site in Ann Arbor, MI—house both the vivarium and the bioanalytical laboratory, enabling sponsors to move from dosing to quantification under a single study plan with one point of contact.

EyeCRO's core technology platform is built on two pillars: an integrated CRO workflow that eliminates cross-vendor sample handoffs, and the proprietary MiDROPS® microemulsion drug ocular penetration system. MiDROPS® uses thermodynamically stable, self-assembling microemulsions to formulate high concentrations of lipophilic small molecules for anterior and posterior segment delivery via eyedrops, and is protected by broad US and international patents covering millions of formulations. The company maintains over 20 validated preclinical disease models spanning anterior segment, inflammation/autoimmune, outer retinal degeneration, inner retinal degeneration, and retinal vascular indications.

The business model is fee-for-service professional services (project-based preclinical research contracts) supplemented by MiDROPS® licensing/royalty revenue. Go-to-market is enterprise B2B, executed through direct outreach, ARVO conference presence, and scientific publication visibility. Pricing is not publicly disclosed and is structured as project-specific quotes. The company is privately held with no disclosed ownership, funding, or revenue figures, and is currently operating with active news publishing and conference participation through May 2026.

Charlesson firmographics

Firmographics
Name
Charlesson
Legal name
EyeCRO
Website
https://charlessonllc.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
1–10 employees
Short description
EyeCRO is a preclinical contract research organization providing integrated ophthalmic drug development services—including in-life efficacy studies, bioanalytical analysis, and the proprietary MiDROPS® eyedrop formulation technology—to pharmaceutical and biotech sponsors developing eye disease therapeutics.
Ownership category
akta.pro rank

Charlesson industry classification

Industry
Product category
Preclinical Contract Research Services
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAKAKAN
Ocular Imaging & Diagnostic Testing Centers

Keywords

  • Preclinical ophthalmic research
  • Contract research services
  • Ophthalmic drug development
  • Bioanalytical laboratory services
  • Preclinical disease models

Where Charlesson is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Charlesson business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Research Services: EyeCRO provides fee-for-service preclinical ophthalmic research contracts, including in-life efficacy studies, bioanalytical services, toxicology/PK studies, and formulation development. Revenue is generated through project-based contracts with pharmaceutical and biotech sponsors.
  2. MiDROPS® Licensing: The company offers its MiDROPS® microemulsion technology for eyedrop formulations, protected by broad patents issued in the US and worldwide. Licensing revenue from the formulation library.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Charlesson product offering

Product offering

Core offering

EyeCRO provides a fully integrated platform for preclinical ophthalmic drug development, delivering in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, and eyedrop formulations under one roof. The company supports pharmaceutical and biotech sponsors with multi-route drug administration, ophthalmic imaging, histology, and 22 validated preclinical disease models, complemented by its proprietary MiDROPS® microemulsion formulation technology for ocular drug delivery.

Product overview

EyeCRO operates as a fully integrated preclinical ophthalmic research platform offering comprehensive drug development services from in-life efficacy studies through bioanalytical quantitation. The core offering combines EyeCRO's research services with MiDROPS®, a proprietary microemulsion drug delivery technology for ophthalmic formulations. Supporting service modules include bioanalytical services (LC-MS/MS, HPLC, ELISA), dosing and drug delivery, histology and pathology, ophthalmic imaging and physiology, and proprietary software and analysis. The company maintains 22 validated preclinical disease models spanning anterior segment, inflammation/autoimmune, outer retinal degeneration, inner retinal degeneration, and retinal vascular conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • MiDROPS®: Microemulsion Drug Ocular Penetration System - a proprietary microemulsion technology for ophthalmic drug delivery using thermodynamically stable, self-assembling vehicles that can formulate high concentrations of drugs for anterior and posterior segment delivery. The technology is protected by broad patents issued in the US and worldwide.

Products and services

  • EyeCRO Preclinical Research Services Fully integrated preclinical ophthalmic drug development platform providing in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, and eyedrop formulations under one roof for pharmaceutical and biotech sponsors.
  • MiDROPS® Microemulsion Drug Ocular Penetration System Proprietary microemulsion technology for eyedrop formulations of lipophilic small molecules, enabling delivery of high drug concentrations to both anterior and posterior eye segments; protected by broad patents issued in the US and worldwide.
  • Bioanalytical Services Laboratory services including LC-MS/MS, HPLC, ELISA, and multiplex immunoassay with optimized ocular tissue extraction protocols for mouse, rat, and rabbit specimens.
  • Dosing & Drug Delivery Services Drug administration services via intravitreal, subretinal, subconjunctival, topical, and systemic routes across mouse, rat, and rabbit species.
  • Histology & Pathology Services Full histological processing, H&E staining, IHC, and digital image quantification for ocular tissue analysis.
  • Ophthalmic Imaging & Physiology Services In vivo retinal imaging services including ERG, OCT, fundus photography, and slit-lamp biomicroscopy across multiple species.
  • Preclinical Disease Models 22 validated preclinical disease models across retinal, corneal, inflammatory, and optic nerve disease areas including Dry Eye Disease, Geographic Atrophy, Diabetic Retinopathy, Retinal Vein Occlusion, and others.

Quantifiable outcome

  • Studies move from dosing to quantification without delays, sample degradation risks, or coordination across vendors

Companies that use Charlesson

Customer profile

Segments1 record

Ideal customer profiles1 record

Charlesson technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Charlesson partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Marseille DeclarationminorOthersEyeCRO is a signatory to the Marseille Declaration, a commitment to ethical business practices and transparency in preclinical research operations.

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Charlesson competitors and assessment

Company assessment

Direct peers

  • Sinclair Research: Sinclair Research is a preclinical CRO with ophthalmic capabilities, AAALAC-accredited facilities, and species expertise (mouse, rat, rabbit, dog, non-human primate). Directly comparable to EyeCRO for in-life preclinical ophthalmic efficacy studies.
  • Absorption Systems: Absorption Systems is a preclinical CRO offering bioanalytical, ADME, and drug delivery services with ophthalmic capabilities. Comparable to EyeCRO for bioanalytical and ocular drug delivery work, with a broader overall ADME portfolio.
  • IONTOX: IONTOX specializes in ocular toxicology, in vitro and ex vivo ocular assays, and preclinical ophthalmic safety assessment. Comparable to EyeCRO's preclinical ocular toxicology/PK service modules, though focused more narrowly on safety.
  • Ora (formerly ORA Clinical Research): Ora is a leading ophthalmic-specialty CRO offering preclinical and clinical research services. It is the closest direct peer to EyeCRO — both target ophthalmic drug development sponsors and compete for similar preclinical ophthalmic contracts, though Ora has a much larger clinical-stage footprint.

Broad incumbents

  • Labcorp Drug Development (formerly Covance): Labcorp Drug Development is a top global CRO offering preclinical and clinical services with ophthalmic drug development capabilities. A broad incumbent that competes with EyeCRO at the high end of ophthalmic sponsor engagements.
  • WuXi AppTec: WuXi AppTec offers preclinical CRO services with ophthalmic capabilities and is one of the largest preclinical research platforms globally. Competes for ophthalmic preclinical contracts from sponsors seeking scale, geographic reach, and integrated chemistry-biology capabilities.
  • Pharmaron: Pharmaron is a global CRO/CDMO with preclinical research capabilities across multiple therapeutic areas including ophthalmology. Provides scale, geographic reach, and integrated chemistry/manufacturing capabilities that small specialist CROs cannot match.
  • Charles River Laboratories: Charles River is one of the largest global preclinical CROs with broad ophthalmic research capabilities across multiple species and indications. Competes with EyeCRO for larger sponsor preclinical ophthalmic contracts but offers many additional therapeutic-area capabilities.
  • Frontage Laboratories: Frontage Laboratories is a CRO providing preclinical and bioanalytical services across multiple therapeutic areas, including ophthalmology following its Absorption Systems acquisition. Competes with EyeCRO for integrated preclinical ophthalmic contracts.

Regional players

  • Bioneeds India: Bioneeds is a preclinical CRO based in India offering ophthalmic efficacy/toxicology services at cost-advantaged pricing. A regional competitor that pressures US-based preclinical CRO economics, particularly for cost-sensitive biotech sponsors.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Charlesson social profiles

Digital presence

Charlesson compliance and trust

Trust signal

Compliance2 records

Charlesson financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Charlesson leadership team

Management profile

Number of profiles

Charlesson funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Charlesson M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Charlesson

What does Charlesson do?

EyeCRO provides a fully integrated platform for preclinical ophthalmic drug development, delivering in-life efficacy studies, bioanalytical analysis, toxicology/PK studies, and eyedrop formulations under one roof. The company supports pharmaceutical and biotech sponsors with multi-route drug administration, ophthalmic imaging, histology, and 22 validated preclinical disease models, complemented by its proprietary MiDROPS® microemulsion formulation technology for ocular drug delivery.

Is Charlesson a public or private company?

Charlesson is a private company. It is classified as unknown and is currently operating.

When was Charlesson founded?

Charlesson was founded in 2004. It employs 1 to 10 people.

Where is Charlesson based?

Charlesson is headquartered in Oklahoma City, United States, in the North America region.

How does Charlesson make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are miDROPS® Licensing.

Who are Charlesson's main competitors?

Direct peers on record are Sinclair Research, Absorption Systems, IONTOX and Ora (formerly ORA Clinical Research). Broad incumbents are Labcorp Drug Development (formerly Covance), WuXi AppTec, Pharmaron, Charles River Laboratories and Frontage Laboratories. Bioneeds India is listed as a regional player.

Does Charlesson have an API?

No public API is recorded for Charlesson.

What industry is Charlesson in?

Charlesson's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers. Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales